Sign in

    Keith Markey

    Scientific Director and Senior Equities Analyst at Griffin Securities

    Keith Markey is a Scientific Director and Senior Equities Analyst at Griffin Securities, specializing in the biotechnology, pharmaceutical, medical device, and research tools sectors. He has covered companies such as Armata Pharmaceuticals and Unilife Medical Solutions, and his career as an equity analyst spans over 25 years with experience in publishing research and management roles at Value Line, Inc., where he initiated coverage across industries and launched a premium advisory publication. Markey started his professional career as a biochemist, publishing over 30 scientific papers, and later earned a Ph.D. in Neurochemistry from the University of Connecticut and an MBA in Finance from NYU Stern School of Business. He held FINRA securities registration during his tenure at Griffin Securities from 2007 to 2018.

    Keith Markey's questions to Armata Pharmaceuticals (ARMP) leadership

    Keith Markey's questions to Armata Pharmaceuticals (ARMP) leadership • Q3 2017

    Question

    Keith Markey of Griffin Securities asked if the company could provide general commentary on the efficacy and safety observed in the six patients treated to date. He also inquired about potential medical conferences in the first half of 2018 where the company or its partners might present detailed findings.

    Answer

    CEO Paul Grint explained that due to the nature of emergency INDs, the company is dependent on the treating institutions to release data publicly first. He confirmed that the therapeutic courses have been well-tolerated but stated it was too early to comment on clinical outcomes until full data collection is complete. Regarding presentation venues, Grint noted that the patient's condition and abstract deadlines are key factors, and it's possible institutions might issue their own press releases, similar to a past case.

    Ask Fintool Equity Research AI